May 9, 2024 Post navigation NetScientific investee company receives £1.8m cash injectionPDS Biotech VERSATILE-002 Phase 2 Clinical Trial Meets Primary Study Endpoints in First Line Recurrent/Metastatic HPV16-Positive Head and Neck Cancer